FDA hopes to get input from patients and providers as it creates new draft guidance for artificial intelligence (AI) lifecycle management and content marketing submissions for AI-enabled devices, an agency official said Wednesday (April 10). The call comes as FDA works to strengthen its purview of AI. “I'm also hopeful that we'll hear feedback from patients and providers who can best tell us what kinds of information they'd like to know about AI-enabled devices in their performance, including their continued...